Correction: Bar-Sela et al. Cannabis Consumption Used by Cancer Patients during Immunotherapy Correlates with Poor Clinical Outcome. Cancers 2020, 12, 2447.

In the original article [...].

Error in Table

In the original article [1], there was a mistake in Table 1 as published. Typing errors were made regarding demographics and medical conditions data. The corrected Table 1 appears below.

Table 1

Demographics and medical conditions.

Characteristics	Cannabis Non-UsersN = 68	Cannabis UsersN = 34	p-Value
Age in years median (range)	69 (18–92)	66 (37–85)
Gender—N (%)
Female	22 (32.4)	10 (29.5)
Male	46 (67.6)	24 (70.5)	0.9399
Performance StatusEastern Cooperative Oncology Group (ECOG)—N (%)
1≤	55 (80.8)	24 (70.5)	0.3568
≥2	13 (19.1)	10 (29.4)	0.3568
Chronic diseases per patient—N (%)
0	22 (32.3)	13 (22.0)	0.7124
1	16 (23.5)	7 (20.5)	0.9332
2 or more	30 (44.1)	14 (41.1)	0.9437
Background diseases—N (%)
Chronic heart disease	18 (26.4)	5 (14.7)	0.2762
Diabetes	17 (25.0)	6 (17.6)	0.5576
High blood pressure	34 (50.0)	13 (34.1)	0.3612
Chronic obstructive pulmonary disease (COPD)	9 (13.2)	3 (8.8)	1
Hyperlipidemia	23 (33.8)	7 (20.5)	0.2491
Other	2 (2.9)	0 (0.0)	1
Type of malignancy—N (%)
Non-small cell lung cancer	37 (54.4)	20 (58.8)	0.8325
Melanoma	25 (36.7)	9 (26.4)	0.414
Renal cell carcinoma	4 (5.8)	2 (5.8)	1
Other	2 (2.9)	3 (8.8)	1
Main site of metastasis—N (%)
Brain	12 (17.6)	8 (13.2)	0.6593
Lungs	39 (57.3)	23 (67.6)	0.4303
Liver	13 (19.1)	11 (32.3)	0.2157
Immunotherapy given as—N (%)
First line of treatment	31 (45.5)	8 (23.5)	0.05178
Second line of treatment or more	37 (54.4)	26 (76.4)	0.05178
Checkpoint therapy—N (%)
Anti PD1: Pembrolizumab or Nivolumab	47 (69.1)	29 (85.2)	0.127
Ipilimumab and Nivolumab	16 (23.5)	4 (11.7)	0.2517
Anti PDL-1: Durvalumab or Atezolizumab	5 (7.3)	1 (2.9)	1

The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. The original article has been updated.